UNASSIGNED: We found 94 heart failure patients between August 2020 and August 2021 who underwent CPET before and after treatment at Mayo Clinic in Florida. 50 patients received OMT and 44 received OMT and SGLT2i therapy. CPET results before and after were compared for each group.
UNASSIGNED: The baseline ejection fraction was not significantly different between groups, with the OMT group at 38% and the SGLT2i group at 33%, p = 0.10. OMT patients were found to have a significantly lower hemoglobin A1c of 5.7 (5.4-6.1) compared to those with SGLT2i therapy of 6.4 (5.8-7.1), p = 0.01. The baseline peak VO2 was 17.3 ml/kg/min (13.3-21.6) in the OMT group and 17.3 ml/kg/min (14.4-18.9) in the SGLT2i group, p = 0.18, not significantly different. The interesting finding is that the follow-up peak VO2 at one year for the OMT group was 17 ml/kg/min (13.3-21.6), which was not significantly different from the SGLT2i group peak VO2 of 17 ml/kg/min (14.6-19.6), p = 0.19. Our study is the first to compare before and after peak VO2 values of the OMT+SGLT2i group to the patient\'s own baseline and we found no significant improvement.
UNASSIGNED: Our single-center data shows no improvement in functional capacity after the addition of SGLT2i therapy to OMT in patients with advanced heart failure. Improved hospitalization and symptoms may be attributed to other numerous effects of SGLT2i such as volume management.
我们在2020年8月至2021年8月期间发现了94名心力衰竭患者,他们在佛罗里达州梅奥诊所接受了CPET治疗前后。50例患者接受OMT治疗,44例患者接受OMT和SGLT2i治疗。比较各组前后的CPET结果。
■两组之间的基线射血分数没有显着差异,OMT组为38%,SGLT2i组为33%,p=0.10。与SGLT2i治疗6.4(5.8-7.1)相比,OMT患者的血红蛋白A1c显着降低,为5.7(5.4-6.1),p=0.01。OMT组VO2基线峰值为17.3ml/kg/min(13.3-21.6),SGLT2i组VO2基线峰值为17.3ml/kg/min(14.4-18.9),p=0.18,差别不明显。有趣的发现是,OMT组一年的随访峰值VO2为17ml/kg/min(13.3-21.6),与SGLT2i组峰值VO217ml/kg/min(14.6-19.6)无显著差异,p=0.19。我们的研究首次将OMT+SGLT2i组前后的峰值VO2值与患者自身的基线进行比较,我们没有发现显著的改善。
■我们的单中心数据显示,在晚期心力衰竭患者中,在OMT中添加SGLT2i治疗后,功能能力没有改善。住院和症状的改善可能归因于SGLT2i的其他许多作用,例如容量管理。